Cystadane
FDA Approves TOBI Podhaler for Bacterial Lung Infection in Cystic Fibrosis Patients »
"The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis
Cystic fibrosis is a genetic disease that affects about 30,000 pediatric and adult patients in the United "...
Cystadane
PATIENT INFORMATION
Patients should be advised of the following information before beginning treatment with Cystadane (betaine anhydrous) :
Dosing and Administration
- Instruct patients and caregivers that Cystadane (betaine anhydrous) should only be taken as directed by their healthcare professional.
- Instruct patients and caregivers to administer Cystadane (betaine anhydrous) as follows:
- Shake bottle lightly before removing cap.
- Measure with the scoop provided.
- Measure the number of scoops as prescribed by their healthcare professional. One level scoop (1.7 mL) is equivalent to 1 gram of betaine anhydrous powder.
- Mix powder with 4 to 6 ounces (120 to 180 mL) of water, juice, milk, or formula until completely dissolved, or mix with food, then ingest mixture immediately.
- Always replace the cap tightly after using, and protect powder from moisture.
Last reviewed on RxList: 4/22/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Cystadane Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
